These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 10502816)
1. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Heymans S; Luttun A; Nuyens D; Theilmeier G; Creemers E; Moons L; Dyspersin GD; Cleutjens JP; Shipley M; Angellilo A; Levi M; Nübe O; Baker A; Keshet E; Lupu F; Herbert JM; Smits JF; Shapiro SD; Baes M; Borgers M; Collen D; Daemen MJ; Carmeliet P Nat Med; 1999 Oct; 5(10):1135-42. PubMed ID: 10502816 [TBL] [Abstract][Full Text] [Related]
2. Inflammatory pathways and cardiac repair: the affliction of infarction. Knowlton KU; Chien KR Nat Med; 1999 Oct; 5(10):1122-3. PubMed ID: 10502807 [No Abstract] [Full Text] [Related]
3. Targeted deletion of class A macrophage scavenger receptor increases the risk of cardiac rupture after experimental myocardial infarction. Tsujita K; Kaikita K; Hayasaki T; Honda T; Kobayashi H; Sakashita N; Suzuki H; Kodama T; Ogawa H; Takeya M Circulation; 2007 Apr; 115(14):1904-11. PubMed ID: 17389263 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Heymans S; Pauschinger M; De Palma A; Kallwellis-Opara A; Rutschow S; Swinnen M; Vanhoutte D; Gao F; Torpai R; Baker AH; Padalko E; Neyts J; Schultheiss HP; Van de Werf F; Carmeliet P; Pinto YM Circulation; 2006 Aug; 114(6):565-73. PubMed ID: 16880329 [TBL] [Abstract][Full Text] [Related]
5. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Heymans S; Lupu F; Terclavers S; Vanwetswinkel B; Herbert JM; Baker A; Collen D; Carmeliet P; Moons L Am J Pathol; 2005 Jan; 166(1):15-25. PubMed ID: 15631996 [TBL] [Abstract][Full Text] [Related]
6. Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction. Agarwal U; Zhou X; Weber K; Dadabayev AR; Penn MS J Mol Cell Cardiol; 2011 Mar; 50(3):426-32. PubMed ID: 20807543 [TBL] [Abstract][Full Text] [Related]
7. Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab. Hammoud L; Lu X; Lei M; Feng Q Basic Res Cardiol; 2011 May; 106(3):459-71. PubMed ID: 21243368 [TBL] [Abstract][Full Text] [Related]
8. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum. Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571 [TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue. González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA Circ Res; 2004 Sep; 95(6):637-44. PubMed ID: 15297377 [TBL] [Abstract][Full Text] [Related]